Vir Biotechnology Closes $172.5 Million Public Offering, Underwriters Fully Exercise Option

summarizeSummary

Vir Biotechnology announced the closing of its public offering, raising approximately $172.5 million in gross proceeds after underwriters fully exercised their option for additional shares.

check_boxKey Events

• Public Offering Closed

  The public offering of common stock, initially announced on February 26, 2026, officially closed on February 27, 2026.

• Significant Capital Raised

  Vir Biotechnology received aggregate gross proceeds of approximately $172.5 million from the offering.

• Underwriters' Option Fully Exercised

  The underwriters fully exercised their option to purchase an additional 2,647,058 shares, bringing the total shares sold to 20,294,117 at $8.50 per share.

auto_awesomeAnalysis

This filing announces the successful closing of Vir Biotechnology's public offering, which was initially disclosed on February 26, 2026. The full exercise of the underwriters' option for additional shares, bringing the total gross proceeds to $172.5 million, represents a significant capital infusion for the company. While the offering is dilutive, securing this substantial funding strengthens the company's balance sheet and provides capital for general corporate purposes, potentially supporting ongoing research and development, including the recently announced collaboration with Astellas for its lead prostate cancer drug.